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Summary 
B cell chronic lymphocytic  leukemia (CLL) is the malignant, monoclonal equivalent of a human 
CD5 + B cell. Previous studies have shown that the V. and VL genes rearranged and/or expressed 
in CLL have few and apparently random mutations. However, in this study, we have found that 
the rearranged V.251  gene, one of the three-membered V.5 family, has extensive and selective 
mutations in B-CLL cells. Somatic mutation at the nudeotide level is 6.03% in B-CLLs whereas 
the somatic mutation levels are much lower in CD5 + and CD5- cord B cells, adult peripheral 
blood B cells, and Epstein-Barr virus-transformed CD5 + B cell lines (0.45, 0.93,  and 1.92%, 
respectively). Complementary determining region I (CDR1) mutation in CLLs is particularly 
prevalent,  and interchanges  in CDRs often lead to acquisition  of charge. Analysis of somatic 
mutations and mutations to charged residues demonstrated that the mutations in CLLs are highly 
selected. 
I 
n the human, the estimated 100-200  VH gene segments 
on chromosome 14 can be divided into six families based 
on nucleotide sequence homology (for review see reference 
1). Family size ranges from greater than 25 (V.3 and V.1) 
to one (V.6),  with the "smaller" families (V.4, V.5,  and 
V.6) displaying  unexpectedly low polymorphism (2).  We 
discovered the V.5 family in a case of familial B cell chronic 
lymphocytic leukemia (B-CLL) 1 (3) and demonstrated that 
one (V.251) of two functional (V.251  and V.32)  and one 
pseudo  (V.15)  members is  rearranged in  about  20%  of 
CLLs examined (4). Others have shown that the V.3 family 
is the most commonly used in CLL, in proportion to its rel- 
ative size, and have confirmed that usage of V.5  and the 
other small  families  is  biased  (5-10).  Although the V.1 
family is underrepresented in CLL with respect to its germ- 
line complexity,  one member (51P1) is observed in 10% of 
CLLs and constitutes 60% of the total V.1 contribution (5). 
Preferential usage of a VK3b gene and the associated cross- 
reactive idiotype has been observed (11, 12). In cases where 
the germline equivalents  could be identified,  V. usage in 
CLL often reflects the fetal repertoire;  i.e., restricted usage 
of "developmentally  regulated" genes (for review see refer- 
ence 13) displaying little or no somatic mutation, This is in 
contrast to the relatively high frequency of V. and VL mu- 
tations seen in follicular lymphoma (14). 
1 Abbreviations used in  this paper: B-CLL,  B  cell chronic  lymphocytic 
leukemia; K/S mutation, replacement/silent  mutation. 
Most B-CLL  express CD5,  a marker present  on <15% 
of normal PBLs or splenocytes, but present on most cord 
blood B cells (for review see references 15 and 16). Human 
CD5 + B cells, and the correspondingly-1 B subset in mice, 
appear to constitute a distinct developmental lineage and share 
important functional similarities. Human and mouse CD5 + 
B cells produce a disproportionate  level of low affinity, poly- 
specific autoantibodies (15-17). It has been proposed (18) that 
CLL could be a consequence of the unique ontogeny of the 
Lyl/CD5 lineage in that repertoires become progressively re- 
stricted, inevitably leading to monoclonality and clones that 
eventually transform. As with B-CLL,  murine Ly-1 B cells 
have generally demonstrated restricted (19) if not unique (20) 
V. repertoires with limited to no somatic mutation (16). 
The prevailing speculation from the above considerations 
is that Ig genes expressed in CLL lack mutations and encode 
polyspecific  autoreactivity. However, data we present here raise 
questions as to the generality of that opinion.  A prototypic 
developmentally regulated V.5 gene (V.251) is extensively 
mutated in most  CD5 + B-CLLs  in  a manner consistent 
with antigen drive, whereas little, if any, mutation of V.251 
is  seen in preimmune and postimmune CD5 + or CD5- 
compartments. 
Materials and Methods 
Patient Materials and Cells.  Frozen  CLL lymphocytes  were ob- 
tained from  40-60-yr-old  patients from W. Blattner  (Environmental 
Epidemiology  Branch, National Cancer Institute, Frederick,  MD), 
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of Texas Southwestern), and C. Lutz (Department of Pathology, 
the University of  Iowa Cancer Center, Iowa City, IA). All samples 
were established (21) by these investigators to be >95% leukemic 
and >90% CD5 +. Two EBV-transformed  cell lines (22) obtained 
from CD5 § adult PBLs, were provided by P. Casali (New York 
University School of  Medicine, NY). Cord blood B cells, collected 
from four delivering  mothers, and PBLs, donated from normal adults 
(30-40-yr-old), were provided  by P. Lipsky (The University  of  Texas 
Southwestern).  Cord  Samples were further  fractionated  into 
CD5 + and CD5-  fractions by doublestaining with CD20  (131; 
Coulter Electronics Inc., Hiahah, FL) and Leu-1 (Becton Dick- 
inson & Co., Mountain View, CA) as previously described (22). 
CD5 positivity of unfractionated cord samples ranged from 50 to 
70%. 
cDNA Synthesis and Genomic DNA Isolation.  Total  RNA was 
isolated from CLL cells (CLL1-9) and EBV-transformed  CD5 + B 
cells (VERGl-14), primed for first-strand  synthesis  with oligo(dT), 
and converted to double-stranded cDNA (23). cDNA was cloned 
into )~gtl0 and libraries, propagated as previously described (24). 
Resulting libraries were doublescreened for V.251 and C# by 
plaque hybridization. Positive clones were subcloned into pUC 
vectors for subsequent analyses. Genomic DNA was isolated from 
CLL10-11, cord blood B cells, and adult PBLs by the method of 
Blin and Stafford (25). 
PCR Amplification and Cloning.  Primers used in  the PCR 
amplifications were synthesized on a DNA synthesizer (Applied 
Biosystems  Inc., Foster City, CA). The 5'-sense primer, dGCACT- 
GAATTCCCTGATTCAAATTTTGTGTCTCC, corresponds to 
the V.251 leader intron (4) preceded by an EcoKI cloning site. 
The  3'-antisense primer, dTACAGGATCCTGAGGAGACGGT- 
GACCAGGGT, corresponds to identical  J.1-J.6 sequences (26) fol- 
lowed by a BamHI cloning site. PCR was performed according 
to recommendations  of the manufacturer  (Perkin-Elmer  Cetus, Nor- 
walk, CT). DNA temphtes  were mixed with 50 pmol of each 
primer, 100/~moldNTPs, and 0.5 U Taq DNA polymerase.  Samples 
were amplified for 30-35 cycles as follows: denaturation at 94~ 
for 1 min, annealing at 63~  for 2 min, and extension at 72~ 
for 3 min. The reaction was extended for 10 min at 72~  after 
the last cycle. 
Cloning and Sequencing.  PCR products were digested and frac- 
tionated on 1% low-melting agarose gels, ligated into EcoRI and 
BamHI sites of pUC19, and transformed into CaCh-competent 
BSJ72 bacteria. All cDNA and PCR-generated clones were se- 
quenced on both strands by the dideoxy chain termination method 
(27) using the M13 universal and reverse-universal primers. For 
CLLs, multiple colonies were sequenced. For PBL B cells and cord 
B cells, clones were randomly chosen and sequenced. Clones with 
identical mutations or germline sequences were verified  as distinct 
by analysis of their N-D-J segments. Sequencing data were ana- 
lyzed with DNAstar  programs (DNAstar Inc., Madison, WI). 
Analysis of Mutations.  All mutations in one set of B cells were 
evaluated as a pool since each set contains a number of clones (11 
in CLLs, 19 in cord B cells, 8 in EBV-transformed  B cells, and 13 
in PBL B cells). A sensitive  binomial probability model used previ- 
ously by Shlomchik et al. (28) was used to evaluate whether the 
observed replacement mutations in CDRs were selective. That is, 
the probability of the number of R mutations in CDRs is: pgco~ 
=  n!/[Rcl~Rl(n-Kcug!)]  x  pr~CDx  X  (1  --  p),-gcDg; where 
RcD~  =  no. of replacement mutation in CDRs; p  =  expected 
probability of K mutations which is the product of the relative 
size of CDKs and the expected R mutations; and n = total muta- 
tion occurred =  RcnR +  S +  2KrR. The same method was also 
used to evaluate the frequency of mutations leading to charged 
residues in CDRs. 
Results 
VH251 Rearranged in CLL B Cells Are Extensively Mutated 
Relative to Cord Blood and Adult PBLs.  We screened 40 CLLs 
and obtained 11  that rearranged V~251,  1 that rearranged 
V.32 and none that rearranged  V.15 (data not shown). This 
biased percentage is consistent with what we (4) have previ- 
ously observed.  Since the focus here is on V.251 mutation, 
the PCR reaction used for cloning from the normal B cell 
population was specific for VH251. We previously showed 
that there were essentially no differences within V.251  se- 
quences obtained from the livers of 10 adult donors (2). This 
lack of polymorphism allows  conclusions to be drawn re- 
garding somatic mutation in the absence of individual germ- 
line sequences. 
Complete nudeotide sequences of rearranged  V.251 genes 
from CLLs, cord blood B cells, CD5 + B cell lines and adult 
PBL are shown in Figs.  1-4. The 11 CLL sequences derived 
from individual cDNA libraries  (CLLs 1-9) or from PCR 
amplification of genomic DNA  (CLLs  10-11).  Genomic 
Southern analysis performed on CLL samples where adequate 
DNA  was  available  revealed  the V.251  rearrangement at 
>90% molarity (3, 4, and data not shown). This agreed with 
the morphological assignment (20,  and see Materials and 
Methods) of leukemic mass, consistent with previous obser- 
vations that CLL is macroscopically monoclonal. Regardless 
of the molecular cloning method, there are extensive somatic 
mutations in VH251 rearranged in CLLs. In contrast, the so- 
matic mutation of rearranged V.251  in  CD5 §  or  CDS- 
cord blood B cells and adult unfractionated PBLs are much 
lower, whereas a relative high level of  mutation occurs in EBV- 
transformed CD5 + B  cell  lines.  Collectively, the average 
mutation level (base mutations/total V. bases) of V,251 uti- 
lized in CLLs is 6.03%, about 13 and 6.5-fold higher than 
those in cord blood B cells, and PBLS, respectively (Table 1). 
The average mutation level of eight sequences  from EBV- 
transformed CD5 +  B  cell  lines  is  1.92%,  about  twofold 
greater than in PBL and fourfold greater than in cord blood 
B calls. These low mutation levels, which include several 100% 
germline sequences, strongly argue against the possibility that 
the extensive mutations in CLLs 1-9 resulted from PCR errors. 
We previously noted the C  to G polymorphism at posi- 
tion 54 in 29% of adults (2, and data not shown). We find 
the equivalent value in adult PBLs (23%), double that value 
in unfractionated cord (53%) but none of the 11 CLLs, 8 
EBV-transformed  CD5 +  B  cells,  nor  4  CD5 +  cord  se- 
quences carried this polymorphism. Although the database 
must be expanded, a CD5 +, subset restricted bias is evident. 
There are no features that distinguish the populations from 
which these samples were selected. 
Lack  of Intraclonal  Variability.  The  excessive  and  un- 
precedented levels of mutation observed in the V,251 CLL 
sequences raised the possibility of an ongoing mutational pro- 
cess. We chose two samples  (CLLs 2 and 10) whose rear- 
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CLLI  ....................................  A ..........  G ....................................................  G- 
CLL2  ...............  C .................................  G .....................  G .............  A--C  ......  G ....  GT 
CLL3  ...........  T--A  .........................................  A .......................  A ..................... 
CLL4  ....................  A ........................................  T ........................................ 
CLL5  ..................................  C ........  C ............  T ............................  T---G  .........  G-- 
CLL6  .....  T .....  A ........................................................  A ................................. 
CLL7  ...............  C ................  C .....  C ............................  G ............  A ............  T ......  A- 
CLL8  ......................  C ..............  T .........  G ...................................................  G-T 
CLL9  ..........................  T ..........................  T .....  A ..........  C ............................... 
CLLI0  ...................................................................................................  G-- 
CLLII  ...................................................................................................... 
VH251 
CLLI 
CLL2 
CLL3 
CLL4 
CLL5 
CLL6 
CLL7 
CLL8 
CLL9 
*****CDRI******  ********************************************* 
AGCTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGCcTGGAGTGGATGGGGATCATCTATCcTGGTGACTcTGATACCAGATACAGCCCGTCCTTC 
-C ...........  C ....  T ..............................................  G ..............  G ..........  C .......... 
--G-G  ........  C ............................  G-AT---TA  ...................  C ..........  T .................  CC- 
-C--TT  ....  C .......  A ................  A ....  C ...............  T .......  T ...............  A .......  T ............. 
GAG  .....  G ....  A ............  A ..............................  G .....  CC ................  T ...................  G 
T--C-TC  .............  A ..........................  A ......  C---C  ..........  T ....  G ....................  A--AC-- 
---C---T---GA  ...................  T ................................  C-A  ......  A ........................... 
CA-C  .......  A ..........  C ...............  G--T  ..................  G-G  ......................  C ......  T---C  ..... 
G ........  G---G  .............................  A .................  C ....  T ....  A ........  C ..................  A-- 
-A ....  C--GC  ............  G ...............................  C-G  .........  A--AC  ........  G ..............  A ....  AT 
CLLI0  --T  ..................................................................  A ..........  G ...........  T ......... 
CLLII  .................................................................  C .................................... 
VH251 
CLLI 
CLL2 
CLL3 
CLL4 
CLL5 
CLL6 
CLL7 
CLL8 
CLL9 
****** 
CAAGGCCAGGTCAccATCTCAGCCGACAAGTCCATCAGCACCGcCTACCTGCAGTGGAGCAGcCTGAAGGCCTCGGACACCGCCATGTATTACTGTGCGAGA 
-G ................................  C---T  ..................................................  C ............ 
....  A ........  G .......  T ................  GT .................  G ........  T---G  .....  G .........  A ..............  C 
....  A ............  T ............  C ................  T---G  ...........................  T ...................... 
....  A ..............  T ........  G .............  A ....  T ..........................  A ........................... 
G ......................  G ..............  T .....  T .....  A .................  A ................................  C 
...................................  a ..............................................................  A--- 
-C-T  ..........  TG ..........  T ...................................  A ..............  T ........................ 
...............................................................................  T ............  T--C-T  .... 
.....  T ...........  G .............  T ......  G .................  T ......  AA ..................................... 
CLLI0  G  G  A  T  .................................................................................................. 
CLLII  ...................................................................................................... 
Figure 1.  Nucleotide  sequences of rearranged V.251 genes in CLLs.  (*)  CDR1  and  CDR2.  (- -  -) identities. 
ranged V.251  genes were highly mutated and were molecu- 
larly  cloned by different methods.  Five to six independent 
sequences obtained from independent bacterial plaques or colo- 
nies were identical within 1-2 bases  (data not shown).  We 
conclude that as in other CD5 + CLL analyses,  intraclonal 
variability  is improbable, suggesting that the observed mu- 
tations occurred before the transformation process. 
Mutation within V,251 Genes Utilized in CLLs Are Highly 
Selected.  Table I summarizes the replacement  and silent mu- 
tations and their ratios with respect to location. The average 
ratio of replacement to silent mutation in CDRs relative to 
framework regions (FWRs) in CLLs is significantly higher 
than  those  in  PBLs,  cord  B  cells,  and  EBV-transformed 
CD5 + and suggests a higher sdection level. In both CD5 + 
and CD5-  B ceils, EBV-transformed  CD5 + B ceils and PBL 
B cells,  several rearranged V,251 genes are identical  to germ- 
line sequences.  Using a binomial probability model to ana- 
lyze differences  among their sdection levels,  we calculated 
the p  values  for finding the number  of observed tLCDp, at 
random (Table 2). Since we have several sequences within each 
set of B cells (11 CLLs,  19 cord B cells, 8 EBV-transformed 
B ceils, and 13 PBL B ceils), we evaluated all mutations within 
a set of B cells as one pool. The p values of cord B cells and 
PBL B cells (0.133 and 0.136) are very close to the expected 
p value (0.173), which suggests there is little, if no, selection 
operating on those B cells. The smallp value (0.034) of EBV- 
transformed  CD5 +  B  cell  lines  is  indicative  of selection. 
However, the very very smaUf value of CLL samples strongly 
indicates  that  selection occurred. 
Usage of  J. and D Segments,  Consistent with the data of 
others (5,  10), most CLLs used J.4 with rearranged V.251 
genes (Table 3). In PBLs, about the same fraction (75%) used 
J.4 and 17% used J.5, which was similar to the percentages 
seen for other V. genes (29). However, CD5 + PBL lines and 
cord blood  B  cells  use J.4  (50%)  less  frequently but J.5 
(40%)  considerably more frequently.  The similar J. usage 
in cord  (mostly  CD5 +)  and  the  adult  CD5 +  lines  is  ex- 
pected if the adult CD5 + population derives from the cord 
CD5 + population which has undergone self-renewal over an 
extended lifetime. From the same logic, discordance between 
cord and CLL usage raises the possibility of different precursors 
for the normal and neoplastic  adult pool. 
As described by others (29), we found inverted D joining, 
D-D joining, inverted D-D joining,  and double inverted D 
joining.  It  is  unusual  that  the  rearranged  V.251  gene  in 
PBL5 (Fig. 4) is recessed  10 nudeotides into the 3' end and 
abutted directly (without N  bases)  to DN4.  Given the low 
numbers analyzed, we did not see any biased usage ofD seg- 
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VH251 GGAGTC'~TGCcGAGGTGCAGCTGG~3CAGTCTGGAGCAGAGGTGi~AGC~CGGGGAGT~TCTG~GATCTCCTGT~GGGTTCTGGATA~AGCT'~2AcC 
CORD1  ...............................  G .....................  G ................................................ 
CORD2  ...................................................................................................... 
CORD3  .....................................................  G ................................................ 
CORD4  .....................................................  G ................................................ 
CORD5  .....................................................................................  T ................ 
CORD6  .........................  C ..............................................................  A ............. 
CORD7  ............  T ........................................  G ................................................ 
CORD8  .....................................................  G ................................................ 
CORD9  .....................................................  G ................................................ 
CORD10  .........................................................................................  T ............ 
*****CDRI******  ********************************************* 
CORD1  -  - 
CORD2  ...................................................................................................... 
CORD3  ...................................................................................................... 
CORD4  ...................................................................................................... 
CORD5  --T ...........  - ...........................................  G ........................................... 
CORD6  .............  C .............................  C .......................................................... 
CORD7  ...................................................................................................... 
CORD8  ...................................................................................................... 
CORD9  ...................................................................................................... 
CORDI0--T  ...........................................................  G ....................................... 
VH251  CAAG•CCAGGTCACCATCTCAGCCGACAAGTCCATcAGCACCGCCTACCTGCAGTGGAGCAGCcTGAAGGCCTCGGACACCGCCATGTATTA•TGTGcGAGA 
CORD1  ...................................................................................................... 
CORD2  ............................................................................  T-T ....................... 
CORD3  ...................................................................................  T .................. 
CORD4  .....................................................................................................  G 
CORD5  .....................................................................................................  G 
CORD6  ...................................................................................................... 
CORD7  ...................  T ........................................  T ......................................... 
CORD8  ...................................................................................................... 
CORD9  ...................................................................................................... 
CORD10  .....................................................................................................  G 
VH251  GGAGTCTGTGCCGAGGTG•AGCTGGTGCAGT•TGGAGCAGAGGTGAAAAAGCCCGGGGAGT•TCTGAAGATCT•cTGTAAGGGTTCTGGATACAGCTTTACC 
CD+I  ...................................................................................................... 
CD+2  ...................................................................................................... 
CD+3  ...................................................................................................... 
CD+4  ...................................................................................................... 
CD-I  .....................................................  G ................................................ 
CD-2  .....................................................  G ..............................................  T- 
CD-3  .....................................................  G ................................................ 
CD-4  .....................................................  G ................................................ 
CD-5  ...................................................................................................... 
*****CDRl******  ********************************************* 
VH251  AGCTA•TGGATC••CTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATcATCTATCCTGGTGACTCTGATAC•AGATACAGCC•GTCCTT• 
CD+I  ...................................................................................................... 
CD+2  .............................................................................................  T ........ 
CD+3  ...................................................................................................... 
CD+4  ...................................................................................................... 
CD-i  ...................................................................................................... 
CD-2  -A .................................................................................................... 
CD-3  ...................................................................................................... 
CD-4  -C .................................  C ..................................  C--G  ............................ 
CD-5  ...........................................................  v .......................................... 
****** 
VH251  CAAGGCCAGGTCACCATCTcAGCCGACAAGTCCATCAGCA•CGCCTACCTGCAGTGGAGCAGCCTGAAGGCCTcGGACA•CGCCATGTATTACTGTGCGAGA 
CD+I  ...................................................................................................... 
CD+2  ...................................................................................................... 
CD+3  ...................................................................................................... 
CD+4  ...................................................................................................... 
CD-I  ...................................................................................................... 
CD-2  .................  A .................................................................................... 
CD-3  ......................  T ...........  C ...................  C ............................................... 
CD-4  .....................................  A ................................................................ 
CD-5  ...................................................................................................... 
Figure 2.  Nucleotide sequences of rea=anged V.251 genes in cord blood B cells unfractionated (A) and &actionated (B) ~r CD5. 
1076  Mutation of V.5 Gene in Human B Cell Chronic Lymphocytic Leukemia VH251  GGAGTC~GTGCCGAGG~GCTGG'~GT~rGGAG~GAGG'~GCCcGGGGAGTC'~C~'~.GATC~cTGT~GGG~1~GGATACAGC~TACc 
VERGI  .................  A .............................................................  T ...............  G ....  T- 
VERG2  ............................  G---G--G  ..........................................................  C ......  T 
VERG3  .................  A ..................................................................................  G- 
VERG4  ...................................................................................................... 
VERG5  ...................................................................................................... 
VERG9  ...................................................  G ..........................................  C .....  A- 
VERG7  ..................................................  A ................................................... 
VERGI4  ...................................................................................................... 
*****CDRI******  ********************************************* 
VH251  A•CTACTC'GAT•G•cTG•GTG•G•CA•ATGcccGGGAAAGG•CTGGAGTG•ATGGGGATCATCTAT•CTGGTGACTCTGATA•CAGATACAGcCcGTcCTTc 
VERGI  GA-C  ............................................................  T .............  A ....................... 
VERG2  -CT .....................................................  A .....................  A ....................... 
VERG3  ...................................................................................  G  .................. 
VER~  ........................................................  C ........................  G .................... 
VERG5  ...................................................................................................... 
VERO%  -A .................................................................................................... 
VERG7  .............  C ...........................................  C ...........  A ................................ 
VERGI4  ...................................................................................................... 
VERGI  .................................................................................................. 
VERG2  -G ...............  T .................................................................................... 
VERG3  ..............  TG ....  G ........................  G--T  ..................................................... 
VER~  ..........................................  C ...................  G ....................................... 
VERG5  ....................................................................................................  A- 
VERGg  ......................  T ..............  C ................................................................ 
VER~  ...................................................................................................... 
VER~  ...................................................................................................... 
Figure 3.  Nucleotide sequences of rea~anged V.251  genes in EBV-trans~rmed  CD5 + B cells ~om adult  PBL. 
VH251  GGA•TCTGTGCCGAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAGCCCGGGGAGTCTCTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACC 
PBL1  ...................................................................................................... 
PBL2  .....................  T ................................................................................ 
PBL3  ................................  C ..................................................................... 
PBL4  ...................................................................................................... 
PBL5  ...................................................................................................... 
PBL6  .............................  A ........................................................................ 
PBL7  .....................................................  G ................................................ 
PBL8  ..........................................  A ...................................  C ..........  G ....  A ....  G-- 
PBL9  .........................  A ............................................................................ 
PBLI0  .....................................................  G ................................................ 
PBLI1  ........................................................................................  A ............. 
PBLI2  .....................................................  G ................................................ 
PBLI3  ...................................................................................................... 
****eCDRI******  ********************************************* 
VH251  AGCTACTGGATCGGCTGGGTGCGCCAGATGCCCGGGAAAGGcCTGGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCcCGTcCTTC 
PBLI  ...................................................................................................... 
PBL2  ...................................................................................................... 
PBL3  -C ...........  C ........................................................................................ 
PBL4  ...................................................................................................... 
PBL5  ...................................................................................................... 
PBL6  ...............................................................................  G-G  .................... 
PBL7  ..........  C .......................................................  A ................................... 
PBI~8  -A ..........................  A-G  ....................................................................... 
PBL9  ...................................................................................................... 
PBLI0  .......................................................................  A .............................. 
PBLI1  .............  C ........  A ............................................................................... 
PBLI2  ...................................................................................................... 
PBLI3  ............................  C ......................................................................... 
VH251  •AAGGCCAGGTCACCATCTCAGCCGACAAGTCCATCAGCACCGCCTACCTG•AGTGGAG•AGCCTGAAGGCCTCGGA•ACCGCCATGTATTACTGTG•GAGA 
PBLI  ...................................................................................................... 
PBL2  .....................................................................................  AA ..............  G 
PBL3  ..................................................................................  G ................... 
PBL4  T  G  T  ................................................................................................... 
PBL5  ............................................................................................ 
PBL6  ...................................................................................................... 
PBL7  .................................................................................................  T .... 
PBL8  .....................................................  - ................................................ 
PBL9  ...................................................................................................... 
PBLIO  --G ................................................................................................... 
PBLII  .....................................................................  A ................................ 
PBLI2  ...................  T .................................................................................. 
PBLI3  A  T  C 
Fipre  4.  Nucleotide sequences of rearranged  V.251  genes in adult  PBL.  In PBL5,  10 nucleotides  at the Y  end were recessed. 
1077  Cai et al. Table  1.  Nucleotide Changes in Rearranged V.251  Genes From Different Types of B-Cells 
Percent base change/bp* 
Samples  Region  Replacement  Average mutation 
(No.)  (Bases)  Replacement  Silent  Total  /Silent  (percent Base mutation) 
No.  ~g  No.  ~o  No.  7o 
FWR1  (99)  17  1.56  18  1.65  35  3.54  0.94 
CLL B  CDK1  (18)  34  17.2  8  4.04  42  21.2  4.26 
cells  FWR2  (42)  10  2.17  11  2.38  21  4.35  0.91  6.03 
(11)  CDR2  (51)  44  7.84  12  2.14  56  9.98  3.67 
FWIL3 (96)  28  2.27  21  2.37  49  4.64  1.33 
FWK1  (99)  6  0.76  5  0.63  11  1.11  1.20 
CD5 + B  CDK1  (18)  9  6.25  2  1.39  11  7.64  4.50 
cells  FWR2  (42)  0  0.00  2  0.60  2  0.60  0.00  1.92 
(8)  CDR2  (51)  7  1.72  1  0.25  8  1,96  7.00 
FWR3  (96)  11  1.43  4  0.52  15  1.95  2.75 
FWK1  (99)  5  0.39  4  0.31  9  0.70  1.25 
PBL B  CDK1  (18)  6  2.56  0  0.00  6  2.56  ND* 
cells  FWR2  (42)  3  0,55  1  0.18  4  0.73  3.00  0.93 
(13)  CDK2  (51)  4  0.60  1  0.15  5  0.75  4.00 
FWR3  (96)  10  0.80  3  0.24  13  1.04  3.33 
FWK1  (99)  4  0.21  2  0.11  6  0.32  2.00 
Cord B  CDK1  (18)  4  1.17  2  0.58  6  1.75  2.00 
cells  FWK2  (42)  1  0.13  1  0.13  2  0.26  1.00  0.45 
(19)  CDK2  (51)  5  0.52  0  0.00  5  0.52  ND* 
FWIL3 (96)  8  0.44  5  0.27  13  0.71  1.00 
* Percent base change/bp was derived by adding the replacement or silent mutations  in all sequences for each region of one sample and dividing 
by the total number of base pairs in each region. 
# ND means no calculation of replacement/silent mutation because of no silent mutation. 
ments in the CLLs. In PBLs and cord B cells, the DXP and 
DN families  are most commonly used, both at 23%. 
No Preference in L  Chain Rearrangements  in CLLs that Use 
V~251.  The demonstrated preference for VK3b (11) and our 
observation of selective mutation and J,4 bias prompted an 
Table  2.  Analysis of Mutation of Rearranged V~251 Genes 
Replacement 
Total  in CDKs 
mutations  (RcDR)  Probability 
Expected 
Cord B cells 
B-CLLs 
CD5 + B cells 
PBL B cells 
examination  of Vr,/VX  status  in  our  CLLs.  Using  PCK 
primers previously shown (30) to be specific for VK1-VJr  fam- 
ilies, we amplified family-specific bands for Vgl-4 with no 
particular  preferences  (data  not  shown).  Failure  to  obtain 
amplification signals in several samples was consistent with 
Table  3.  Usage  of  JH Segments in Rearranged V.251  Genes 
J,  CLL  PBL  Cord  CD5 §  Total 
segments  B cells  B cells  B cells  B lines  usage 
.  0  1(8%)  0  1(12%)  2 
0.173  j.2  0  0  1 (10%)  0  1 
45  9  0.133  j.3  0  0  0  0  0 
258  78  1.31￿  10 -7  j.4  8  (73%)  9  (75%)  5  (50%)  4  (50%)  26 
64  16  0.034  j.5  2  (18%)  2  (17%)  4  (40%)  3  (38%)  11 
55  10  0.136  j.6  1 (9%)  0  0  0  1 
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CLLI 
CLL2 
CLL3 
CLL4 
CLL5 
eLL6 
CLL7 
CLL8 
eLL9 
CLLIO 
CLLI1 
*CDRI*  ******CDR2******* 
-4  1  i0  20  30  40  50  60  70  80  90 
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Figure 5.  Deduced  amino acid sequences  of V.251 genes utilized in CLLs. 
the cell surface phenotypic assignment  of k  Although the 
sample size is relatively small, no biases are apparent. 
Analysis of Deduced Amino Acid Sequences and Mutations to 
Charged Residues from  II,251  Utilized in CLLs.  Compar- 
ison  of the mutated V.251  amino acid sequences derived 
from CLL cells with those derived from germline V.251 re- 
vealed clustering of extensive changes in CDRs (Fig. 5). In 
CDR1,  54%  of the amino acids are replaced, many with 
charged residues. All six CDR1 residues of germline V,251 
are uncharged, whereas 31% of the substituted residues are 
charged.  Serine 31 is a hotspot, with 8/11  sequences sub- 
stituted at this position. Particularly within CDRs, common 
mutations were shared among 2-3 sequences. Both conser- 
vative and nonconservative changes were observed, the most 
striking being the neutral to charge conversions at positions 
33 (W~R), 67 (G~D), and 78 (S~R). The expected fre- 
quency of mutations leading to charged residues in FWRs 
is 4.6%, but there is a much higher percentage of observed 
mutations to charged residues in CDRs (23.7%), which is 
indicative of positive selection. Using the binomial proba- 
bility model to assess this observation, we obtained ap value 
of 3.88  x  10 -is, whereas the expected p value is 10 -2. This 
indicates that a strong selective force is operative in gener- 
ating charged residues within CDRe. The combined effect 
of the extensive mutations in CDKs and FWKs leads to a 
significant increase in overall positive charge. 
Discussion 
V.251 is a member of the small human V.5 gene family 
(4) that displays remarkably little polymorphism (2). That 
allowed  us  to  compare the  nucleotide sequences of the 
V.251 gene rearranged in different cell populations without 
the corresponding germline counterparts.  9  of 11  V.251 
genes utilized in CLLs have dusters of extensive mutation. 
Using a binomial probability  model, we found that muta- 
tions within CDRs of CLLs are highly selective. The selec- 
tion level is much higher than those observed in the other 
B cell populations  studied here (Tables 1 and 2) or in the 
two previous reports of antigen-specific EBV-transformants 
(31) or hybridomas (32) that express a V.251 H chain. The 
deduced amino acid sequences of the CLL were remarkable 
for the high ratio of CDR replacement with charged residues. 
The binomial probabilities confirmed that these mutations 
are also highly selected and occur at much higher than ex- 
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pected frequency. In CDK1,  half of the germline neutral 
residues are replaced, and a third of these replacements are 
with charged residues. A similar CDK1 focus was observed 
in the two V.251-utilizing  antibodies  previously reported 
(31, 32). Both had four CDR1 interchanges. All are found 
among our CLL pool although none are charged. 
Several groups  have studied VL and V. genes utilized  in 
human CLLs and found little or no mutations (5-11). As 
with V.251,  some of the V. genes analyzed are considered 
to  be  developmentally  regulated,  in  that  they are  over- 
represented in the fetal repertoire  (13). There does not ap- 
pear to be any phenotypic differences among the CLLs ana- 
lyzed in other studies (5-11) and ours. Within our 11 samples, 
there were no features that distinguished the two CLLs that 
expressed V,251  with  only a  few mutations.  In  all  the 
studies, sequences were derived exclusively from IgMs. One 
feature  that  distinguishes  the V.5  family from all  other 
human V. families is that two members (V.215 and V.15) 
express abundant germline transcripts in CLLs (4, 33). The 
correlation between germline transcription  and subsequent 
V to DJ recombination (34) conceivably could be extended 
to somatic mutation. Mutation of a productively regulated 
V~ transgene requires its transcription (35). However, gemaline 
V.251 transcripts in CLLs are not mutated (33), nor would 
one expect the selective mutation pattern we have observed 
to be generated from an antigen-independent mechanism. 
Regardless of why V.251 is susceptible to mutation, the 
result is at variance with the prevailing view of low affinity, 
polyspecific antibody expression  in  CLL.  Instead,  in  the 
majority of our CLLs, the V.251 sequences appear to be de- 
rived from prototypic high affinity antibodies. Selection could 
occur after the malignant transformation event. A model for 
B cell receptor (surface Ig idiotype)-mediated leukemogen- 
esis, first elaborated by McGrath et al. (36) and potentially 
relevant to our situation,  was provided by Mann et al. (37). 
In their analysis of B-CLL in HTLV-I endemic Caribbeans, 
a heterohybrid of one B-CLL demonstrated strict specificity 
for the gag 41 surface protein of HTLV-I. Inconsistent with 
this model is our lack of intraclonal sequence variability. Also 
we found no correlation of V. usage with that of Vx3b (or 
any other L chain), nor with that of D. segment. This puts 
unprecedented requirements on V. sequence/variation.  We 
favor the alternative model that mutation precedes transfor- 
mation.  We envisage two general categories  of CD5 §  B 
cells: those that do not somatically mutate and those that do.  The  latter  are  the  precursor  lineage  for  most  of the 
V,251-utilizing  CLL (with  CLL being an  exception)  and 
potentially may carry additional biases, such as J. preference. 
The antigen drive apparently operative on V~251 may de- 
rive from self-reactivity.  Most human autoantibodies are pro- 
duced by CD5 + B cells that preferentially use small V, fam- 
ilies (15-17). Although not the rule with IgMs, extensively 
mutated sequences have been served in some autoantibodies 
(38-40). The unusual acquisition of charged residues we ob- 
served is reminiscent of high affinity antinucleic acid responses 
(41).  Some CD5 + B cells expressing V,251 may be stimu- 
lated and selected by self-antigens to proliferate constantly, 
subjecting these cells to abnormal expansion and eventual trans- 
formation into tumors. Alternatively, our data is equally com- 
patible with  a foreign antigen  providing  the drive. 
The  potential  for  V.251  diversification  in  the  normal 
preimmune environment is extremely limited, irrespective of 
the CD5 +/CDS-  compartment.  That V,251 in adult EBV- 
transformed  CD5 §  cells  show relative high  mutation  ex- 
tends findings that human CD5 + cells are susceptible to an 
antigen-driven diversification mechanism (31, 38-40). As with 
limited germline polymorphism, absence of mutation could 
be an advantage for a developmentally regulated V. gene. In 
the case of V.251 expressers,  CLL could be a natural conse- 
quence of repertoire restriction via expansion of given clones 
by a "super" antigen.  Thus the normal inability to develop 
this high affinity response would divert  the inevitable dis- 
aster of monoclonality. 
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